Volume 14, Issue 1 pp. 55-59

Effect of oral cyclosporin A in children with Staphylococcus aureus-colonized vs. S. aureus-infected severe atopic dermatitis

Rita Bunikowski

Rita Bunikowski

Department of Pediatric Pneumology and Immunology, Humboldt University of Berlin,

Search for more papers by this author
Martin Mielke

Martin Mielke

Robert Koch-Institut, Berlin,

Search for more papers by this author
Matthias Bräutigam

Matthias Bräutigam

Novartis Pharma GmbH, Nürnberg,

Search for more papers by this author
Harald Renz

Harald Renz

Department of Clinical Chemistry and Molecular Diagnostics, Klinikum der Philips-Universität, Marburg, Germany

Search for more papers by this author
Ulrich Wahn

Ulrich Wahn

Department of Pediatric Pneumology and Immunology, Humboldt University of Berlin,

Search for more papers by this author
First published: 21 February 2003
Citations: 14
Rita Bunikowski, MD, Charité Campus Virchow-Klinikum, Humbold University Berlin, Department of Pediatric Pneumology and Immunology, Augustenburger Platz 1, 13353 Berlin, Germany
Tel.: +49 30 450 566182
Fax: +49 30 450 566931
E-mail: [email protected]

Abstract

Atopic dermatitis (AD) is frequently associated with skin colonization or infection with Staphylococcus aureus strains producing exotoxins. The aim of this investigation was to evaluate the effect of oral cyclosporin A (CsA) on disease severity and bacterial counts in colonized and infected patients. Eleven children with severe AD (SCORAD index >50, mean objective SCORAD score >40) were treated for 8 weeks with 2.5–5 mg/kg CsA. In five patients, the skin was only colonized with S. aureus whereas the remaining six patients presented clinically relevant suppurative S. aureus skin infections characterized by small pustules, crustings, pus and increased pruritus in the presence of S. aureus as determined by contact sampling and culture which regularly resulted in the indication for antibiotic treatment. Clinical and microbiological investigations were performed before and after CsA therapy. Clinical signs and symptoms of AD improved in all patients with a reduction in mean SCORAD index from 74 to 29 (p < 0.001). However, disease severity and bacterial counts were more reduced by CsA in the colonized patients compared with the patients with clinical overt infections. In conclusion, treatment with CsA resulted in an improvement of clinical symptoms in children suffering from severe AD. However, anti-infective treatment administered before immunomodulatory therapy is likely to be decisive for the long-term therapeutic effect.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.